TITLE:
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

CONDITION:
HIV Infections

INTERVENTION:
Itraconazole

SUMMARY:

      To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive
      or negative persons with blastomycosis or histoplasmosis.
    

DETAILED DESCRIPTION:

      Patients are randomized to receive IV itraconazole for 2 days, then either itraconazole
      daily for 5 days or amphotericin B daily for 7 days. IV treatment is followed by
      consolidation with oral itraconazole for up to 1 year.
    

ELIGIBILITY:
Gender: All
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV positive or negative status.

          -  Blastomycosis or histoplasmosis.

          -  Life expectancy of at least 1 week.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Liver disease.

          -  Self-limiting fungal disease.

          -  Very severe fungal disease such as meningeal involvement.

          -  Acute respiratory disease.

        Concurrent Medication:

        Excluded at any time:

          -  Terfenadine.

          -  Astemizole.

          -  Oral midazolam.

          -  Triazolam.

          -  Cisapride.

          -  Phenytoin.

          -  Phenobarbital.

          -  Rifampin.

          -  Rifabutin.

        Excluded during oral consolidation:

          -  H2 blockers.

          -  Chronic antacids.

          -  Omeprazole.

          -  Lansoprazole.

        Patients with the following prior condition are excluded:

        Hypersensitivity to azole antifungals.

        Prior Medication:

        Excluded at any time:

        More than 3 days of amphotericin B, fluconazole, or ketoconazole.

        Excluded within 2 weeks prior to study entry:

          -  Phenytoin.

          -  Phenobarbital.

          -  Rifampin.

          -  Rifabutin.
      
